Effects of E2HSA, a Long-Acting Glucagon Like Peptide-1 Receptor Agonist, on Glycemic Control and Beta Cell Function in Spontaneous Diabetic db/db Mice

Journal of Diabetes Research
Shao-cong HouZhu-fang Shen

Abstract

Glucagon like peptide-1 (GLP-1) receptor agonists such as exendin-4 have been widely used but their short half-life limits their therapeutic value. The recombinant protein, E2HSA, is a novel, long-acting GLP-1 receptor agonist generated by the fusion of exendin-4 with human serum albumin. In mouse pancreatic NIT-1 cells, E2HSA activated GLP-1 receptor with similar efficacy as exendin-4. After single-dose administration in ICR mice, E2HSA showed prolonged glucose lowering effects which lasted up to four days and extended inhibition on gastric emptying for at least 72 hours. Chronic E2HSA treatment in db/db mice significantly improved glucose tolerance, reduced elevated nonfasting and fasting plasma glucose levels, and also decreased HbA1c levels. E2HSA also increased insulin secretion and decreased body weight and appetite. Furthermore, immunofluorescence analysis showed that E2HSA increased β-cell area, improved islet morphology, and reduced β-cell apoptosis. In accordance with the promotion of β-cell function and survival, E2HSA upregulated genes such as Irs2, Pdx-1, Nkx6.1, and MafA and downregulated the expression levels of FoxO1 and proapoptotic Bcl-2 family proteins. In conclusion, with prolonged glucose lowering effects a...Continue Reading

References

Jan 1, 1985·Advances in Protein Chemistry·T Peters
Feb 28, 1998·The EMBO Journal·L O'ConnorD C Huang
Jul 18, 2002·The Journal of Biological Chemistry·Mark S DennisLisa A Damico
Jul 30, 2002·Diabetes·Catherine S LeeKlaus H Kaestner
Sep 10, 2002·American Journal of Physiology. Endocrinology and Metabolism·Bidda RolinLotte Bjerre Knudsen
Dec 28, 2002·Diabetes·Alexandra E ButlerPeter C Butler
Jan 10, 2003·The Journal of Clinical Endocrinology and Metabolism·T VilsbøllJ J Holst
Jul 5, 2003·Genes & Development·Ulupi S JhalaMarc Montminy
Sep 17, 2003·The Journal of Pharmacology and Experimental Therapeutics·Christian ThorkildsenJørgen Søberg Petersen
Feb 11, 2005·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Orville G KoltermanAlain D Baron
May 11, 2005·Proceedings of the National Academy of Sciences of the United States of America·Jonathan C SchislerChristopher B Newgard
Jul 20, 2005·Diabetic Medicine : a Journal of the British Diabetic Association·M N FeinglosUNKNOWN Liraglutide Dose-Response Study Group
Nov 8, 2005·The Journal of Biological Chemistry·Sunmin ParkMorris F White
Mar 7, 2006·Cell Metabolism·Daniel J Drucker
Mar 15, 2006·International Journal of Obesity : Journal of the International Association for the Study of Obesity·C M MackA A Young
Sep 26, 2006·Canadian Journal of Physiology and Pharmacology·Morris F White
Oct 12, 2007·Physiological Reviews·Jens Juul Holst
Oct 19, 2007·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Shannon Reagan-ShawNihal Ahmad
Dec 22, 2007·Nature Reviews. Molecular Cell Biology·Richard J Youle, Andreas Strasser
Oct 27, 2009·Proceedings of the National Academy of Sciences of the United States of America·Mira M SachdevaDoris A Stoffers
Apr 29, 2010·Diabetes·Taka-aki MatsuokaMunehide Matsuhisa
Jan 14, 2011·Diabetes Care·UNKNOWN American Diabetes Association
Jul 2, 2011·Trends in Endocrinology and Metabolism : TEM·Yan Hang, Roland Stein
Jan 1, 2012·FEBS Open Bio·Zhanxiang Wang, Debbie C Thurmond
May 21, 2013·Cell Metabolism·Jonathan E Campbell, Daniel J Drucker
Aug 21, 2013·Nature Reviews. Endocrinology·Tadahiro Kitamura
Apr 25, 2014·Diabetes·Decheng RenKenneth S Polonsky
May 1, 2013·Expert Review of Endocrinology & Metabolism·Tracy Setji, Mark Feinglos

❮ Previous
Next ❯

Methods Mentioned

BETA
ELISA
PCR

Software Mentioned

Excel
ImageJ
Prism
Primer
GraphPad
BLAST

Related Concepts

Related Feeds

Antidiabetic Cellular Plasticity

This feed focuses on mechanisms that underlie cellular plasticity as a treatment for diabetes and other degenerative diseases.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.